S-1 can lead to less hand-foot syndrome (HFS) than capecitabine16 and several studies have demonstrated the efficacy of SOX for metastatic CRC17,18, As the AVOID trial demonstrated that adding dexamethasone could help prevent oxaliplatin-induced hypersensitivity reactions19, we mixed dexamethasone (6.6 mg) into the oxaliplatin. Here, PSMD1 is linked to Hand-foot syndrome.